Astromech is a privately held company tracked for investment-relevant business and technology developments.
This slot renders the company's funding history: dates, rounds, amounts, valuations and lead investors once populated in data/funding-rounds.json.
Astromech applies a focused AI model to evolutionary genomics — leveraging Colossal's massive elephant dataset — to identify conserved cancer-resistance mechanisms (e.g., p53 overexpression) and predict drug targets across diseases, requiring far less compute than broad foundation models.